Revenio Group Corporation’s January-March 2023 Interim Report will be published on Thursday, April 27, 2023, approximately at 09.00 a.m. (EEST). The report will be available at https://www.reveniogroup.fi/en/investors/reports_and_presentations. An audiocast and teleconference call for analysts and investors will be held in English at 3.00 p.m. (EEST) on the same day.
Audiocast: https://revenio.videosync.fi/q1-2023-results
To ask questions, please join the teleconference by registering using the following link: http://palvelu.flik.fi/teleconference/?id=10010581
After the registration, you will be provided with phone numbers and a conference ID to access the conference. To ask a question, please press *5 on your telephone keypad to enter the queue.
A recording of the audiocast will be published on https://www.reveniogroup.fi/en/ after the event.
For further information, please contact
Robin Pulkkinen, CFO, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
Distribution
Key media
www.reveniogroup.fi/en
Revenio Group in brief
Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.
In 2022, the Group’s net sales totaled EUR 97.0 million, with an operating profit of EUR 29.7 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.
REVENIO GROUP OYJ 
